Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.
Integra LifeSciences Holdings Corporation (Nasdaq: IART) is frequently featured in healthcare and capital markets news as a global medical technology company focused on neurosurgery, tissue reconstruction, and regenerative care. Its news flow, as reflected in recent press releases, spans financial results, regulatory milestones, clinical technology updates, policy developments, and investor conference participation.
Investors following IART news will see regular quarterly earnings announcements, typically accompanied by detailed segment commentary for Codman Specialty Surgical and Tissue Technologies, as well as discussions of organic revenue trends, adjusted profitability metrics, and management’s outlook. These releases are often paired with notices of conference calls and webcasts accessible through the company’s investor relations channels.
Beyond financial reporting, Integra issues news on regulatory and clinical developments. Recent examples include FDA 510(k) clearance for expanded use of the CUSA Clarity Ultrasonic Surgical Aspirator System in cardiac surgery and updates on neurosurgical technologies such as CereLink, Aurora, Mayfield devices, and Durepair Dura Regeneration Matrix. The company also highlights its presence at major clinical meetings, including the Congress of Neurological Surgeons Annual Meeting, where it showcases its neurosurgical portfolio.
Policy and reimbursement developments are another theme in Integra’s news. The company has commented on CMS rules affecting Medicare beneficiary access to skin substitutes, noting the inclusion of its dermal regenerative templates, decellularized dermal scaffolds, and amniotic tissue membranes, as well as specific brands like Integra matrices, PriMatrix, Cytal, and AmnioExcel.
In addition, IART news covers leadership and governance updates, such as the appointment of a chief medical officer and participation by senior executives in investor healthcare conferences. For readers and investors, the IART news page offers a centralized view of Integra’s financial performance, product and regulatory milestones, policy environment, and corporate developments.
Campbell Soup Company (NYSE:CPB) announced the appointment of Carrie L. Anderson as Executive Vice President and Chief Financial Officer, effective February 6. Anderson will oversee the finance function including controllership, corporate financial planning, and analysis, among other areas. She succeeds Mick Beekhuizen, who transitioned to President of the Meals & Beverages division. Anderson joins from org value="NASDAQ-NMS:IART"Integra LifeSciences where she served as CFO since 2019. With a background in diverse industries and a strong financial acumen, her leadership is expected to enhance Campbell's growth and performance.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced preliminary financial results for the fourth quarter and full-year 2022, revealing expected revenues of $397-$398 million for Q4, a 2% decrease reported but a 3% organic increase year-over-year. For the full year, revenues are projected at $1,557-$1,558 million, reflecting a 1% reported increase and 4% organic growth. Adjusted earnings per diluted share for both periods are expected to exceed prior guidance. The company also plans a $150 million share repurchase program in 2023 and will present at the J.P. Morgan Healthcare Conference on January 11.
Integra LifeSciences (NASDAQ: IART) announced that its CEO, Jan De Witte, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 PM ET. A live webcast will be accessible through Integra's investor relations website. The company, recognized for its regenerative tissue technologies and neurosurgical solutions, aims to support clinicians in delivering optimal patient care. Integra boasts a robust portfolio of high-quality brands.
Integra LifeSciences (NASDAQ:IART) has completed its acquisition of Surgical Innovation Associates (SIA). This strategic move aims to enhance Integra's position as a leader in implant-based breast reconstruction (IBBR) procedures, as stated by Robert T. Davis, Jr., Executive VP at Integra. The company emphasizes its commitment to improving patient outcomes through innovative technologies. Integra is known for its extensive portfolio in regenerative tissue technologies and neurosurgical solutions, promising a focus on high-quality patient care.
Integra LifeSciences (NASDAQ:IART) announced the acquisition of Surgical Innovation Associates (SIA) for $50 million, with potential additional payments totaling $90 million based on performance metrics. This strategic acquisition enhances Integra's product offerings in plastic and reconstructive surgery, particularly in breast reconstruction, addressing a growing market opportunity. The FDA is currently reviewing Integra's pre-market approval application for its existing SurgiMend product, and the transaction is expected to be dilutive to earnings in year one but accretive by year three.
Integra LifeSciences (Nasdaq: IART) has reached a definitive agreement to acquire Surgical Innovation Associates (SIA) for up to $140 million. The transaction includes $50 million at closing and an additional $90 million contingent upon achieving specified milestones. SIA's DuraSorb® technology, which has seen 80-100% annual revenue growth, will enhance Integra's surgical portfolio and expedite market entry for plastic and reconstructive surgical devices. Closing is expected by year-end, pending customary conditions.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported Q3 2022 revenues of $385 million, a decrease of 0.4% year-over-year, with a 3.5% increase on an organic basis. GAAP earnings per diluted share rose to $0.60, compared to $0.51 last year. The company raised its EPS outlook to $3.29-$3.33 and reaffirmed revenue guidance between $1,551-$1,563 million, indicating organic growth of 3.7%-4.5%. The TWC business was sold for $28.8 million, and cash flow from operations reached $68 million. Full-year guidance reflects adjustments due to foreign currency impacts.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) plans to release its third quarter 2022 financial results on October 26, 2022, before market opening. This will be followed by a conference call hosted by the management team at 8:30 a.m. ET. Investors can access the call by dialing 866-571-0905 with passcode 1121226# or through a live webcast on the company’s website. A replay will be available until November 7, 2022.
Integra LifeSciences (NASDAQ: IART) announced the appointment of Harvinder Singh as executive vice president and president of its international business. Singh brings over 20 years of experience from Abbott Laboratories, where he held various senior roles, including vice president of global commercial operations in the vascular sector. His expertise is expected to support Integra's growth strategy in international markets. Singh holds degrees in chemistry and biology from Punjab University and an MBA from the University of Indore, along with completing the Harvard Business School’s Advanced Management Program.
Summary not available.